Research Article
Evaluating Drug Risk Using GAN and SMOTE Based on CFDA’s Spontaneous Reporting Data
Table 5
Evaluation metrics based on the actual ADR data.
| Classifier | Label | Precision | Recall | F1 | Accuracy (%) |
| Model 1 (RF) | 0 | 0.89 | 0.99 | 0.94 | | 1 | 0.80 | 0.36 | 0.50 | 88.63 | 2 | 0.72 | 0.28 | 0.40 | | Macro-avg | 0.81 | 0.54 | 0.61 | | Weighted-avg | 0.88 | 0.89 | 0.87 | |
| Model 2 (SMOTE + RF) | 0 | 0.98 | 0.95 | 0.97 | | 1 | 0.80 | 0.90 | 0.85 | 94.65 | 2 | 0.72 | 0.94 | 0.81 | | Macro-avg | 0.83 | 0.93 | 0.88 | | Weighted-avg | 0.95 | 0.95 | 0.95 | |
| Model 3 (FS_GAN + SMOTE + RF) | 0 | 0.99 | 0.99 | 0.99 | | 1 | 0.92 | 0.93 | 0.93 | 97.90 | 2 | 0.96 | 0.94 | 0.95 | | Macro-avg | 0.96 | 0.95 | 0.95 | | Weighted-avg | 0.98 | 0.98 | 0.98 | |
|
|